Los Angeles Capital Management & Equity Research Inc. reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 43.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 99,306 shares of the medical device company’s stock after selling 76,120 shares during the quarter. Los Angeles Capital Management & Equity Research Inc. owned about 0.11% of DexCom worth $11,827,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of the company. Laurel Wealth Advisors LLC acquired a new stake in DexCom during the fourth quarter worth about $26,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in DexCom during the fourth quarter worth about $33,000. Canton Hathaway LLC acquired a new stake in DexCom during the first quarter worth about $41,000. First Hawaiian Bank grew its position in DexCom by 75.6% during the fourth quarter. First Hawaiian Bank now owns 395 shares of the medical device company’s stock worth $47,000 after buying an additional 170 shares in the last quarter. Finally, Bremer Trust National Association acquired a new stake in DexCom during the fourth quarter worth about $49,000. 96.15% of the stock is currently owned by institutional investors.
In other news, Director Mark G. Foletta sold 1,000 shares of DexCom stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $150.28, for a total value of $150,280.00. Following the completion of the transaction, the director now owns 4,052 shares in the company, valued at $608,934.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Steven Robert Pacelli sold 1,667 shares of DexCom stock in a transaction that occurred on Friday, February 22nd. The shares were sold at an average price of $144.67, for a total transaction of $241,164.89. The disclosure for this sale can be found here. Insiders sold 96,530 shares of company stock valued at $13,231,236 in the last quarter. 1.80% of the stock is currently owned by corporate insiders.
NASDAQ DXCM traded up $0.16 during trading on Wednesday, reaching $118.75. 782,873 shares of the company traded hands, compared to its average volume of 1,315,650. The company has a current ratio of 7.18, a quick ratio of 6.75 and a debt-to-equity ratio of 1.57. The company has a market capitalization of $10.53 billion, a price-to-earnings ratio of 395.83 and a beta of 0.73. DexCom, Inc. has a 1-year low of $85.76 and a 1-year high of $156.16.
DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, May 1st. The medical device company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.12. DexCom had a negative net margin of 11.51% and a positive return on equity of 8.45%. The company had revenue of $280.50 million during the quarter, compared to analysts’ expectations of $246.10 million. During the same quarter in the previous year, the company posted ($0.30) earnings per share. DexCom’s quarterly revenue was up 52.1% compared to the same quarter last year. On average, analysts predict that DexCom, Inc. will post 0.77 earnings per share for the current year.
A number of equities research analysts recently weighed in on the company. BidaskClub downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Tuesday, March 26th. Zacks Investment Research raised DexCom from a “hold” rating to a “buy” rating and set a $138.00 target price on the stock in a research report on Monday, May 6th. BMO Capital Markets lifted their target price on DexCom from $167.00 to $172.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. Raymond James decreased their target price on DexCom from $160.00 to $150.00 and set an “outperform” rating on the stock in a research report on Thursday, May 2nd. Finally, Piper Jaffray Companies lifted their target price on DexCom to $173.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $152.25.
ILLEGAL ACTIVITY WARNING: “DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Los Angeles Capital Management & Equity Research Inc.” was originally posted by Sundance Herald and is the sole property of of Sundance Herald. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://sundanceherald.com/2019/05/22/los-angeles-capital-management-equity-research-inc-trims-position-in-dexcom-inc-dxcm.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: Closed-End Mutual Funds
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.